Electrolyte Blood Press.  2013 Jun;11(1):1-8. 10.5049/EBP.2013.11.1.1.

The Role of V2 Receptor Antagonists in the Treatment of Hyponatremia

• Palmer BF

• KMID: 2168394
• DOI: http://doi.org/10.5049/EBP.2013.11.1.1

Abstract

No abstract available.

MeSH Terms

Hyponatremia
Receptors, Vasopressin
Receptors, Vasopressin

Reference

1. Palmer BF, Alpern RJ. Integrated response to abnormalities in tonicity. In : Seldin DW, Giebisch G, editors. Clinical Disturbances of Water Metabolism. New York: Raven Press Ltd;1993. p. 273–295.

2. Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother. 2003; 37:1694–1702. PMID: 14565794.

3. Nedvetsky P, Tamma G, Beulshausen S, Valenti G, Rosenthal W, Klussmann E. Regulation of aquaporin-2 trafficking. Handb Exp Pharmacol. 2009; 190:133–157. PMID: 19096775.

4. Chen S, Jalandhara N, Batlle D. Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists. Nat Clin Pract Nephrol. 2007; 3:82–95. PMID: 17251996.

5. Zeltser D, Rosansky S, va Rensburg H, Verbalis J, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007; 27:447–457. PMID: 17664863.

6. Schrier R, Gross P, Gheorghiade M, Berl T, Verbalis J, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006; 355:2099–2112. PMID: 17105757.

7. Koshimizu T, Nasa Y, Tanoue A, et al. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci. 2006; 103:7807–7812. PMID: 16682631.

8. Palmer B. Pathogenesis of ascites and renal salt retention in cirrhosis. J Investig Med. 1999; 47:183–202.

9. Adrogue H, Madias N. Hyponatremia. N Engl J Med. 2000; 342:1581–1589. PMID: 10824078.

10. Sterns R, Nigwekar S, Hix J. The treatment of hyponatremia. Semin Nephrol. 2009; 29:282–299. PMID: 19523575.

11. Palmer BF. Hyponatremia in the intensive care unit. Semin Nephrol. 2009; 29:257–270. PMID: 19523573.

12. Ghali J, Farah J, Daifallah S, Zabalawi H, Zmily H. Conivaptan and its role in the treatment of hyponatremia. Drug Des Devel Ther. 2009; 3:253–268.

13. Verbalis J. Vaptans for the treatment of hyponatremia: How who when and why. Nephrol Self Assess Program. 2007; 6:199–209.

14. Berl T, Quinttnat-Pelletier F, Verbails J, Schrier RW, Bichet Dg, Ouyang J, et al. Saltwater investigoators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010; 21:705–712. PMID: 20185637.

15. Decaux G. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Semin Nephrol. 2009; 29(3):239–256. PMID: 19523572.

16. Gankam Kengne F, Andres C, Sattar L, Melot C, Decaux C. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM. 2008; 101:583–588. PMID: 18477645.

17. Kinsella S, Moran S, Sullivan M, Molloy M, Eustace J. Hyponatremia Independent of Osteoporosis is Associated with Fracture Occurrence. Clin J Am Soc Nephrol. 2010; 5:275–280. PMID: 20056759.

18. Verbalis JG, Barsony J, Sugimura Y, et al. Hyponatremia-Induced Osteoporosis. J Bone Miner Res. 2010; 25:554–563. PMID: 19751154.

19. Wald R, Jaber B, Price L, Upadhyay A, Madias N. Impact of Hospital-Associated Hyponatremia on Selected Outcomes. Arch Intern Med. 2010; 170(3):294–302. PMID: 20142578.

20. Waikar S, Mount D, Curhan G, et al. Mortality after Hospitalization with Mild, Moderate, and Severe Hyponatremia. Am J Med. 2009; 122:857–865. PMID: 19699382.